Distinct assembly profiles of HLA-B molecules
- PMID: 24790147
- PMCID: PMC4117407
- DOI: 10.4049/jimmunol.1301670
Distinct assembly profiles of HLA-B molecules
Abstract
MHC class I polymorphisms are known to influence outcomes in a number of infectious diseases, cancers, and inflammatory diseases. Human MHC class I H chains are encoded by the HLA-A, HLA-B, and HLA-C genes. These genes are highly polymorphic, with the HLA-B locus being the most variable. Each HLA class I protein binds to a distinct set of peptide Ags, which are presented to CD8(+) T cells. HLA-disease associations have been shown in some cases to link to the peptide-binding characteristics of individual HLA class I molecules. In this study, we show that polymorphisms at the HLA-B locus profoundly influence the assembly characteristics of HLA-B molecules and the stabilities of their peptide-deficient forms. In particular, dependence on the assembly factor tapasin is highly variable, with frequent occurrence of strongly tapasin-dependent or independent allotypes. Several polymorphic HLA-B residues located near the C-terminal end of the peptide are key determinants of tapasin-independent assembly. In vitro refolded forms of tapasin-independent allotypes assemble more readily with peptides compared to tapasin-dependent allotypes that belong to the same supertype, and, during refolding, reduced aggregation of tapasin-independent allotypes is observed. Paradoxically, in HIV-infected individuals, greater tapasin-independent HLA-B assembly confers more rapid progression to death, consistent with previous findings that some HLA-B allotypes shown to be tapasin independent are associated with rapid progression to multiple AIDS outcomes. Together, these findings demonstrate significant variations in the assembly of HLA-B molecules and indicate influences of HLA-B-folding patterns upon infectious disease outcomes.
Figures






References
-
- Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823–836. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI044115/AI/NIAID NIH HHS/United States
- U01-AI35040/AI/NIAID NIH HHS/United States
- U01-AI35042/AI/NIAID NIH HHS/United States
- U01 AI035041/AI/NIAID NIH HHS/United States
- UM1 AI035043/AI/NIAID NIH HHS/United States
- AI044115/AI/NIAID NIH HHS/United States
- U01-AI35041/AI/NIAID NIH HHS/United States
- U01-AI35039/AI/NIAID NIH HHS/United States
- U01 AI035040/AI/NIAID NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- UM1-AI35043/AI/NIAID NIH HHS/United States
- K07 CA140360/CA/NCI NIH HHS/United States
- U01 AI035042/AI/NIAID NIH HHS/United States
- R56 AI044115/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources